High infectious risk organ donors in kidney transplantation: Risks, benefits, and current practices

Dialysis and Transplantation

Volumn 39, Issue 5, 2010, Pages 186-189

  Kucirka, Lauren M ^a   Dagher, Nabil N ^a   Montgomery, Robert A ^a   Segev, Dorry L ^a,b   Singer, Andrew L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Epidemiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT INFECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERMETHOD COMPARISON; KIDNEY DONOR; KIDNEY TRANSPLANTATION; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; VIRUS TRANSMISSION;

EID: 77953068182     PISSN: 00902934     EISSN: 19326920     Source Type: Journal    
DOI: 10.1002/dat.20442     Document Type: Review

References (41)

1. United States Renal Data System. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007 December 11th, 2007.
2. U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. 2007 OPTN/SRTR Annaul Report: Transplant Data 1997-2006. HRSA website: www.ustransplant.org/annual-reports/arhives/2007.htm. Accessed April 1, 2010.
3. Rogers MF, Lawton KE, Moseley RR, Jones WK, National Center for Infectious Diseases. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. 1994. Available at: www.cdc.gov/MMWR/preview/mmwrhtml/00031670.htm. Accessed May 2, 2008.
4. Kucirka LM, Alexander C, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant. 2009;9(3):620-628.
5. Duan KI, Englesbe MJ, Volk ML. Centers for Disease Control 'high-risk' donors and kidney utilization. Am J Transplant. 2009. Dec 2 [Epub ahead of print].
6. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl. 2008;14(11):1603-1608.
7. Calabrese F, Angelini A, Cecchetto A, Valente M, Livi U, Thiene G. HIV infection in the first heart transplantation in Italy: fatal outcome. Case report. APMIS. 1998;106(4):470-474.
8. Chazouilleres O, Mamish D, Kim M, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet. 1994;343(8890):142-146. (Pubitemid 2013315)
9. De Feo TM, Poli F, Mozzi F, Moretti MP, Scalamogna M. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc. 2005;37(2):1238-1239. (Pubitemid 40590848)
10. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg. 1997;3(2):105-111. (Pubitemid 27114021)
11. Grady D. Four Transplant Recipients Contract HIV. 2007. Available at: www.nytimes.com/2007/11/13/health/13cnd-organ.html?em&ex=1195189200&en= 4aa09291f000fe7b&ei=5087%0A. Accessed June 18, 2008.
12. Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the united states: data reviewed by the OPTN/UNOS disease transmission advisory committee. Am J Transplant. 2009;9(8):1929-1935.
13. Krajden M, Bishai F, Quan C, et al. Multi-organ donor transmission of hepatitis C virus to five solid organ transplant recipients and lack of transmission to corneal transplant recipients. Clin Diagn Virol. 1995;3(2):113-121.
14. Moraleda G, Barcena R, Del Campo S, Oton E, Moreno J, Foruni JR. De novo HBV infection caused by an anti-HBc positive donor in a vaccinated liver transplant recipient in spite of anti-HBs response. Am J Transplant. 2006;6(2):438-440. (Pubitemid 43382187)
15. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991;325(7):454-460.
16. Pfau PR, Rho R, DeNofrio D, et al. Hepatitis C transmission and infection by orthotopic heart transplantation. J Heart Lung Transplant. 2000;19(4):350-354. (Pubitemid 30211657)
17. Provisional Public Health Service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome. 1985. Available at: www.cdc.gov/mmwr/preview/ mmwrhtml/00033029.htm. Accessed September 12, 2008.
18. Rogers MF, Lawton KE, Moseley RR, Jones WK. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. 1994. Available at: www.cdc.gov/MMWR/preview/mmwrhtml/ 00031670.htm. Accessed September 12, 2008.
19. OPTN. Policy 2.2. Available at: www.optn.org/policies-AndBylaws/policies. asp. Accessed March 25, 2010.
20. Minimum Procurement Standards for an Organ Procurment Organization. 2008. Available at: www.unos.org/PoliciesandBylaws2/policies/pdfs/policy-2.pdf. Accessed September 12, 2008.
21. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion. 2003;43(6):788-798.
22. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion. 1995;35(2):91-97.
23. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol. 2006;36(suppl 1):S23-29.
24. Kolk DP, Dockter J, Linnen J, et al. Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol. 2002;40(5):1761-1766. (Pubitemid 34493155)
25. Singer AL, Kucirka LM, Namuyinga R, Hanrahan C, Subramanian AK, Segev DL. The high-risk donor: viral infections in solid organ transplantation. Curr Opin Organ Transplant. 2008;13:400-404.
26. Borst A, Box AT, Fluit AC. False-positive results and contamination in nucleic acid amplification assays: suggestions for a prevent and destroy strategy. Eur J Clin Microbiol Infect Dis. 2004;23(4):289-299. (Pubitemid 38669939)
27. Kucirka LM, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL. Formal policies and special informed consent are associated with higher provider utilization of CDC high-risk donor organs. Am J Transplant. 2009;9(3):629-635.
28. Kucirka LM, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL. provider utilization of high-risk donor organs and nucleic acid testing: results of two national surveys. Am J Transplant. 2009;9(5):1197-1204.
29. Freeman RB, Cohen JT. Transplantation risks and the real world: what does 'high risk' really mean? Am J Transplant. 2009;9(1):23-30.
30. Schweitzer EJ, Perencevich EN, Philosophe B, Bartlett ST. Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. Am J Transplant. 2007;7(6):1515-1525. (Pubitemid 46776240)
31. Reese PP, Feldman HI, Asch DA, et al. Transplantation of kidneys from donors at increased risk for blood-borne viral infection: recipient outcomes and patterns of organ use. Am J Transplant. 2009;9(10):2338-2345.
32. Roland ME, Stock PG. Solid organ transplantation is a reality for patients with HIV infection. Curr HIV/AIDS Rep. 2006;3(3):132-138. (Pubitemid 44874999)
33. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355-365.
34. Locke JE, Montgomery RA, Warren DS, Subramanian A, Segev DL. Renal transplant in HIV-positive patients: long-term outcomes and risk factors for graft loss. Arch Surg. 2009;144(1):83-86.
35. Kucirka LS, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2009. March 2010. [Epub ahead of print].
36. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant. 2004;4(12):2032-2037.
37. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol. 2002;13(12):2974-2982.
38. Halpern SD, Shaked A, Hasz RD, Caplan AL. Informing candidates for solid-organ transplantation about donor risk factors. N Engl J Med. 2008;358(26):2832-2837. (Pubitemid 351930862)
39. Kucirka LM, Subramanian AK, Montgomery RA, Segev DL. Provider response to a rare but highly publicized transmission of HIV through solid organ transplantation. Arch Surg. 2010. In press.
40. UNOS. Communication of donor history. 2008. Available at: www.unos.org/SharedContentDocuments/2008JuneBOD-CombinedPolicyNoticeFINAL.pdf. Accessed September 12, 2008.
41. United Network of Organ Sharing. Standard Transplant Analysis and Research (START) Dataset Files [CD-ROM]. Richmond, VA: UNOS; 2009.